Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026
DOI: 10.1016/j.eimce.2026.503201 ↗Kurz gefasst
Fallbericht in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026. Verfasst von Borja González Rodríguez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: borjasturias@hotmail.com. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Dermatomycoses, Mucormycosis, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Mucormycosis are invasive fungal infections caused by fungi of the order Mucorales that classically affect profoundly immunosuppressed patients. Recently, cases have emerged in patients receiving Bruton tyrosine kinase inhibitors like Ibrutinib, used for chronic lymphocytic leukemia (CLL). METHODS: We report a 58-year-old man with CLL on Ibrutinib and Venetoclax who developed a rapidly progressing necrotic ulcer on his leg after minor trauma. Histopathology revealed angioinvasive, non-septate hyphae; Rhizopus spp. was confirmed by culture. He was treated with surgical debridement, liposomal amphotericin B, and isavuconazole, with good outcome. We also reviewed published cases of cutaneous mucormycosis in Ibrutinib-treated patients. RESULTS: Including our case, seven patients were identified. Most presented with single necrotic limb lesions after minor trauma. Median age was 69.5 years; median Ibrutinib exposure was 3 years. Liposomal amphotericin B was the most used antifungal; surgery was performed in over half of the patients. CONCLUSIONS: Cutaneous mucormycosis is an emerging complication in Ibrutinib-treated patients. Early diagnosis and combined antifungal and surgical treatment are crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: borjasturias@hotmail.com.
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Zitieren
APA
González Rodríguez, B., Arroyo Andrés, J., Gotor Rivera, A., Pérez de Ayala Balzola, A., Rodríguez Peralto, J. L., & Postigo Llorente, C. (2026). Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2026.503201
Vancouver
González Rodríguez B, Arroyo Andrés J, Gotor Rivera A, Pérez de Ayala Balzola A, Rodríguez Peralto JL, Postigo Llorente C. Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026. doi:10.1016/j.eimce.2026.503201
BibTeX
@article{GonzlezRodrguez2026,
author = {González Rodríguez, Borja and Arroyo Andrés, Jorge and Gotor Rivera, Alfonso and Pérez de Ayala Balzola, Ana and Rodríguez Peralto, José Luis and Postigo Llorente, Concepción},
title = {Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2026},
doi = {10.1016/j.eimce.2026.503201}
}
EUVIMED